West Pharmaceutical Services Overview
Latest ROE for West Pharmaceutical Services: 18.89% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow18.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for WST is 18.89%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside West Pharmaceutical Services's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, WST currently prints 18.89% for ROE, while the sector average sits near -100.59%. That is roughly 118.8% above the sector mean. Large gaps often invite a closer look at West Pharmaceutical Services's growth, margins, and balance sheet.
Return on Equity shows how effectively West Pharmaceutical Services converts resources into returns. At 18.89%, WST may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting WST's ROE (18.89%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack West Pharmaceutical Services's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
